ArticleMedicine2026
Novel oral chidamide and valganciclovir regimen for EBV-PTLD post-hematopoietic stem cell transplantation: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleEpstein-Barr virus-related posttransplant lymphoproliferative disorder (EBV-PTLD) is a serious and potentially fatal complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). PATIENT CONCERNS: We report a case of a 46-year-old male who developed EBV-PTLD 3 months after haploidentical HSCT for refractory acute myeloid leukemia. The patient presented with a persistent cough and a pulmonary nodule that increased in size from 8 mm × 5 mm to 27 mm × 25 mm over 4 weeks. Increased EBV loads were also detected (peripheral blood EBV sorting: EBV-T DNA 2.09E+03, EBV-B DNA 1.16E+03, EBV-NK DNA 7.89E+02 copies/mL; alveolar lavage fluid: 114 sequences; later rising to 3304). DIAGNOSES: Diagnosis was confirmed by biopsy which showed EBV-positive pleomorphic lymphoproliferative disorder with extensive necrosis.
interventionsTreatment consisted of an oral regimen of chidamide (5 mg once daily) and valganciclovir (450 mg twice daily). OUTCOMES: After 8 weeks of therapy, the pulmonary lesion decreased to 19 mm × 16 mm, and peripheral blood EBV-DNA levels declined significantly. LESSONS: The patient achieved clinical remission with manageable side effects, including neutropenia and thrombocytopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.